SNPMiner Trials by Shray Alag


SNPMiner SNPMiner Trials (Home Page)


Report for Clinical Trial NCT02956278

Developed by Shray Alag, 2020.
SNP Clinical Trial Gene

The Effects of BCRP Q141K on Allopurinol Pharmacokinetics and Dynamics

Subjects will undergo a placebo and allopurinol phase to better understand the effects of the reduced function BCRP Q141K variant on allopurinol pharmacokinetics and pharmacodynamics.

NCT02956278 Chronic Gout Hyperuricemia
MeSH:Hyperuricemia
HPO:Hyperuricemia

2 Interventions

Name: Allopurinol

Type: Drug
Group Labels: 1

Allopurinol

Name: Placebo

Description: lactose placebo pill
Type: Other
Group Labels: 1

Placebo


Primary Outcomes

Measure: Allopurinol/Oxypurinol Renal Clearance

Time: as determined by blood/urine levels taken over the course of one week

Measure: Uric Acid Levels

Time: as determined by blood/urine levels taken over the course of one week

Secondary Outcomes

Measure: Allopurinol/Oxypurinol steady state concentrations

Time: as determined by blood/urine levels taken over the course of one week

Measure: Allopurinol/Oxypurinol AUC

Time: as determined by blood levels taken over the course of one week

Purpose: Basic Science

Allocation: Non-Randomized

Parallel Assignment


There is one SNP

SNPs


1 Q141K

The Effects of BCRP Q141K on Allopurinol Pharmacokinetics and Dynamics. --- Q141K ---

The Effects of BCRP Q141K on Allopurinol Pharmacokinetics and Dynamics Subjects will undergo a placebo and allopurinol phase to better understand the effects of the reduced function BCRP Q141K variant on allopurinol pharmacokinetics and pharmacodynamics. --- Q141K ---

The Effects of BCRP Q141K on Allopurinol Pharmacokinetics and Dynamics Subjects will undergo a placebo and allopurinol phase to better understand the effects of the reduced function BCRP Q141K variant on allopurinol pharmacokinetics and pharmacodynamics. --- Q141K --- --- Q141K ---



HPO Nodes


HPO: